Abstract
Current Proteomics
Title: Meeting Report The Third Annual PepTalk Meeting: The Human Proteome
Volume: 1 Issue: 2
Author(s): Sean R. Gallagher
Affiliation:
Abstract:
Export Options
About this article
Cite this article as:
Gallagher R. Sean, Meeting Report The Third Annual PepTalk Meeting: The Human Proteome, Current Proteomics 2004; 1 (2) . https://dx.doi.org/10.2174/1570164043379442
DOI https://dx.doi.org/10.2174/1570164043379442 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Mass spectrometry data acquisition and analysis for proteomics
The Thematic Issue on "Mass spectrometry data acquisition and analysis for proteomics" aims to explore the latest advancements and challenges in the field of proteomics through the lens of mass spectrometry. Proteomics, the large-scale study of proteins and their functions, plays a crucial role in understanding various biological processes and ...read more
Peptides: State-of-Art and Commercialisation Hurdles
The Editors of the Current Proteomics (CP) journal are highly privileged to welcome scientists to submit their scientific research and review articles to be considered for publication in the upcoming thematic issue. The topics should cover various aspects of peptides in regard to their synthetic methodologies, formulation approaches, pharmacological challenges, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Essential Polymers Helping Patients with Obesity
Current Applied Polymer Science New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry New Robotic Technologies in Cancer Colon Screening
Clinical Cancer Drugs Toxicology of Tributyltin in Mammalian Animal Models
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Apoptosis in Drug Response
Current Pharmacogenomics α-Methylene-γ-lactones as a Novel Class of Anti-leukemic Agents
Anti-Cancer Agents in Medicinal Chemistry Chios Gum Mastic: A Review of its Biological Activities
Current Medicinal Chemistry Immunotherapy Approaches in Cancer Treatment
Current Pharmaceutical Biotechnology Chemical Characterization and Antioxidant Potential of <i>Athroisma proteiformis</i> Essential Oil
The Natural Products Journal Nitric Oxide and its Antithrombotic Action in the Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Colchicine: An Ancient Drug with Multiple Benefits
Current Pharmaceutical Design Role of Second-Line Systemic Treatment Post-Docetaxel in Metastatic Castrate Resistant Prostate Cancer- Current Strategies and Future Directions
Anti-Cancer Agents in Medicinal Chemistry Development of Peptide and Protein Based Radiopharmaceuticals
Current Pharmaceutical Design 100% Human Monoclonal Antibodies in Oncology: Hype or Breakthrough?
Current Topics in Medicinal Chemistry New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Pharmacokinetic Study of Weekly (Days 1-5) Low-dose S-1 in Patients with Non-Small-Cell Lung Cancer
Reviews on Recent Clinical Trials The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Synthesis of Isoxazole Moiety Containing Thieno[2,3-d]pyrimidine Derivatives and Preliminarily in vitro Anticancer Activity (Part II)
Anti-Cancer Agents in Medicinal Chemistry Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets